SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________ FORM 10-KSB (Mark One) [X] ANNUAL REPORT UNDER SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2000 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to____________ Commission File Number: 0-17843 REGAL ONE CORPORATION (name of small business issuer as specified in its charter) Florida 95-4158065 (State or other jurisdiction of (IRS Employer Incorporation or Organization) Identification No.) C/O Christopher H. Dietrich, Attorney at Law 11300 W. Olympic Blvd., Suite 800 Los Angeles, California 90064 (Address of Principal Executive Offices) (310) 312-6888 (Issuer's telephone number) Securities registered under section 12(b) of the Exchange Act: None Securities registered under section 12(g) of the Exchange Act: Common Stock, no par Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES [X] NO [ ] Check here if the disclosure of delinquent filers in response to Item 405 of Regulation S-B is not contained in this form, and no disclosure will be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this 10-KSB or any amendment to this Form 10-KSB. [ ] Revenues for the year ending December 31, 2000 were $ -0-. The aggregate market value of the voting stock held by non-affiliates of the Company, based upon the average bid price of the common stock on July 5, 1999 was approximately $436,954. As of December 31, 2000, the Company had 1,269,217 shares of common stock issued and outstanding and 208,965 shares of convertible preferred stock issued and outstanding, each of which is convertible into 100 shares of the Company's common stock. REGAL ONE CORPORATION FORM 10-KSB for the fiscal year ended December 31, 2000 TABLE OF CONTENTS Part I Item 1. Description of Business Item 2 Description of Property Item 3 Legal Proceedings Item 4 Submission of Matters to a Vote of Security Holders Part II Item 5 Market for the Company's Common Equity and Related Stockholder Matters Item 6 Management's Discussion and Analysis and Plan of Operation Item 7 Financial Statements Item 8 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure Part III Item 9 Directors, Executive Officers, Promoters and Control Persons; Compliance with Section 16(a) of the Exchange Act Item 10 Executive Compensation Item 11 Security Ownership of Certain Beneficial Owners and Management Item 12 Certain Relationships and Related Transactions Item 13 Exhibits and Reports on Form 8-K SIGNATURES PART I ITEM 1. DESCRIPTION OF BUSINESS General and Background Regal One Corporation (the "Company") is a Florida corporation originally incorporated as Electro-Mechanical Services, Inc. ("EMS") in 1959. In 1974, Mr. Israel Rubinstein, acquired the Company, then named EMS, which at the time had no operations. Pursuant to the merger agreement, Mr. Rubinstein transferred the assets of Regal Muffler Centers, a franchise network of over 100 muffler shops that he founded in 1972 and solely owned, into EMS. In March of 1975, EMS amended its certificate of incorporation and changed its name to Regal International Holding Co., Inc. In 1976, the Company sold substantially all of its assets, but Mr. Rubinstein retained control of the Company. In June 1988, after merging with its wholly owned Nevada Subsidiary, Regal One Corporation, the Company changed its name to Regal One Corporation, but remained a Florida entity. From 1987 to 1992, the Company was engaged in the acquisition and holding of real estate, primarily in the Western United States. Until the end of 1992, the Company's assets consisted primary of irrevocable options to acquire the real estate in exchange for shares of the Company's common stock. Generally, the Company would issue to the Seller of the property shares of its common stock with a fair value equal to the value of the real estate on the date of the agreement. During 1992, due to the protracted depressed national real estate market, the Company decided to abandon its real estate operations and pursue opportunities in the pharmaceutical and health fields. Xechem, Inc. In January, 1993, the Company executed an agreement to acquire Xechem, Inc. The total costs incurred by the Company relating to the proposed investment in Xechem were approximately $1,012,000. On January 14, 1994, the agreement with Xechem was canceled and a settlement agreement was entered into whereby the Company received 60,000 shares of common stock of Xechem, $250,000 in cash and the satisfaction of $131,000 of liabilities at no cost to the Company. Accordingly, based on this settlement agreement, the net realizable cost of the Xechem investment was adjusted down to the estimated fair value of $150,000, resulting in a loss of $142,645 in 1994. The Company then sold 20,000 shares of Xechem (one third of its investment) for $50,000. In 1995, the Company distributed the remaining 40,000 shares of Xechem common stock to consultants or advisors of the Company for services provided to the Company. Carbonex Systems Corporation In August, 1995, the Company acquired in a reverse acquisition all of the issued and outstanding shares of common stock of Carbonex Systems Corporation ("Carbonex"), a development stage Delaware Corporation, owning certain exclusive rights to a proprietary emission reduction system for internal combustion engines. To effect the acquisition, the Company issued a total of 464,000 shares of 8.75% convertible, participating voting Series B Preferred Stock (the "Preferred Stock"). Each share of Preferred Stock is convertible into 100 shares of common stock and has 100 votes for each vote allowed to a share of common stock. In June, 1996, the Company entered into a Stock Exchange Settlement Agreement and General Release whereby the Company exchanged all of the issued and outstanding shares of common stock of Carbonex for 255,035 shares of Preferred Stock owned by Gene Bemel and certain members of his family. As part of the agreement, the Company assumed certain specified accounts payable totaling approximately $61,000. The net impact of this transaction was a gain on sale of $295,803, primarily due to the forgiveness of debt and accrued interest payable (see note 3 to the Financial Statements). As a result of this transaction, the Company has issued and outstanding 208,965 shares of Preferred Stock. Quality Franchise Systems, Inc. In November, 1996, the Company executed a Letter of Intent to acquire all of the issued and outstanding stock of Quality Franchise Systems, Inc. However, a final agreement was never completed, and the Company is no longer pursuing this acquisition. Safesight, Inc. In July, 1997, the Company announced the acquisition of Safesight, Inc., a development-stage company engaged in the design of vehicle anti-collision warning products for the automobile, commercial vehicle, recreational vehicle and motorcycle markets. In August, 1997, the parties elected not to proceed with this transaction because of the parties' inability to obtain adequate funding for operations. Infectech, Inc. In April, 1998, the Company entered into an agreement to merge a newly formed subsidiary of the Company with Infectech, Inc.("Infectech"). Infectech, founded In 1989, is a development- stage biotechnology company which owns 15 patents for the rapid identification and antibiotic sensitivity testing of 34 disease- causing bacteria. On August 5, 1998, the Company announced that Infectech, Inc. had unilaterally acted to terminate the merger agreement between the two parties. Infectech stated as its reason that it had not been successful in raising the requisite $300,000 prior to June 30, 1998. Infectech further notified the Company that it proposed to arbitrate the return of $56,000 paid by Infectech for legal fees and certain other merger-related expenses of the Company, as per the merger agreement. On November 18, 1998, the Company and Infectech, Inc. resolved the matter subject to arbitration, with the Company issuing 10,000 shares of restricted common stock to Infectech, Inc. on November 24, 1998. Current Operations During 1999, the Company had no business activity, but continued to pursue acquisition candidates. Employees Mr. Israel Rubinstein was the President, Chief Executive Officer and a Director of the Company since 1975, except for the period from August 7, 1995 to June 1, 1996, when Mr. Gene Bemel was President as part of the Carbonex acquisition. Mr. Israel Rubinstein died in January of 2001 and the company appointed Richard Babbitt, a director, as President and Chief Executive Officer. The Company has no full-time employees and no employee of the Company earned in 1997, or is currently earning annually, as much as $50,000. (See Item 10, "Executive Compensation") ITEM 2. DESCRIPTION OF PROPERTY As of December 31, 2000, the Company did not and currently does not own or lease any real property. The Company's current street and mailing address is: Regal One Corporation 11300 West Olympic, Suite 800 Los Angeles, California 90064 (310) 312-6888 The Company did not and currently does not have any tangible fixed assets as of December 31, 2000. ITEM 3. LEGAL PROCEEDINGS The Company has no current legal proceedings pending. ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS For the fourth quarter of the fiscal year ending December 31, 2000, there were no matters submitted to a vote of security holders through the solicitation of proxies or otherwise. PART II ITEM 5. MARKET FOR COMPANY'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS Market Information The Company's shares of common stock trade on the National Association of Securities Dealers' OTC Bulletin Board under the symbol "RONE". The following table sets forth the range of high and low daily closing prices of the Company's common stock per quarter as provided by NASDAQ Trading and Marketing Services (which reflect inter-dealer prices without retail mark-up, mark-down or commission and may not necessary represent actual transactions). Common Stock 2000 1999 1998 High Low High Low High Low Quarter ended: March 31: .500 .312 .5313 .25 1.28 .3125 June 30: .437 .281 .5625 .4063 1.4375 .625 September 30: .406 .250 .4688 .3125 .875 .253 December 31: .469 .312 .4063 .3125 .375 .25 Quarter ended March 31, 2001: High: .375 Low: .25 Shareholders As of March 31, 2001, there were approximately 605 shareholders of record, inclusive of those brokerage firms and/or clearing houses holding the Company's common shares in "street name". Dividend Matters The Company has not paid or declared any dividends upon its common stock since its inception, and does not contemplate or anticipate paying any dividends in the foreseeable future. Any future declaration of cash or stock dividends will be at the discretion of the Board of Directors and will depend upon the financial condition, capital requirements, earnings, and liquidity of the Company as well as other factors that the Board of Directors may deem relevant. ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION The following discussion should be read in conjunction with the Company's financial statements and notes thereto included in Item 7 of this Form 10-KSB report. The Company was incorporated in 1959 in Florida. Since that time, the Company has owned and operated, and subsequently sold off, a number of businesses. During 1987, the Company pursued a policy of using its common stock to purchase, either in fee simple or as an irrevocable option to purchase, a number of parcels of real estate, in the form of commercial, industrial, residential and development stage land parcels. In 1992, market conditions for real estate were no longer deemed to be favorable and the Company decided to abandon its real estate operations and pursue other courses of operation. In January, 1993, the Company agreed to acquire Xechem, Inc., a development-stage company engaged in the research and development of pharmaceuticals from plants and other naturally-occurring sources. However, the transaction was terminated in January, 1994 pursuant to a settlement agreement. In August, 1995, the Company acquired all of the issued and outstanding common stock of Carbonex Systems Corporation ("Carbonex"). In June, 1996, the Company entered into a Stock Exchange, Settlement Agreement and General Release whereby the Company exchanged with its then-principal shareholders, Gene Bemel and members of his family, all of the issued and outstanding common stock of Carbonex for 255,035 shares of Preferred Stock. In November, 1996, the Company executed a Letter of Intent to acquire all of the issued and outstanding stock of Quality Franchise Systems, Inc. However a final agreement was never completed and the Company is no longer pursing this acquisition. In July, 1997, the Company announced the acquisition of Safesight, Inc., a development-stage company engaged in the design of vehicle anti-collision warning products. However, in August, 1997, the parties elected not to proceed with the transaction because of the inability to obtain adequate funding for operations. In April, 1998, the Company entered into an agreement to merge a newly formed subsidiary of the Company with Infectech. Infectech, founded in 1989, is a development-stage biotechnology company which owns 15 patents for the rapid identification and antibiotic sensitivity testing of 34 disease-causing bacteria. On August 5, 1998, the Company announced that Infectech, Inc. had unilaterally acted to terminate the merger agreement between the two parties. Infectech stated as its reason that it had not been successful in raising the requisite $300,000 prior to June 30, 1998. Infectech further notified the Company that it proposed to arbitrate the return of $56,000 paid by Infectech for legal fees and certain other merger-related expenses of the Company, as per the merger agreement. On November 18, 1998, the Company and Infectech, Inc. resolved the matter subject to arbitration, with the Company issuing 10,000 shares of restricted common stock to Infectech, Inc. on November 24, 1998. (See Item 1, "Description of Business - Current Operations") Plan of Operation Through December 31, 2000, the Company had no active business operations but continued to pursue acquisition candidates. The independent auditor's report for the fiscal year ended December 31, 2000 will include an explanatory paragraph calling attention to a going concern issue. The Company has suffered recurring losses and, at December 31, 2000, has a stockholders' deficit. The Company's ability to continue as a going concern depends upon the Company obtaining additional financing to satisfy the operating needs of the Company and/or complete a successful merger. Liquidity and Capital Resources - December 31, 2000 Compared to December 31, 1999. During the current year, the Company had continuing losses from operations. There can be no assurances that the Company will be able to secure long-term borrowings with which to finance its future operations. The Company does not currently have any established bank lines of credit. The Company's lack of liquidity is reflected in the table below, which shows comparative working capital (current assets less current liabilities) which is an important measure of the Company's ability to meet its short-term obligations. December 31, 2000 December 31, 1999 Working Capital (deficit) $ (26,789) $ (254,478) The Company's financial condition at December 31, 2000 reflects an immediate inability to meet its short-term obligations. At December 31, 2000, the Company had $2,336 cash on hand. The liabilities of the Company at December 31, 2000 aggregated $272,125, consisting primarily of accounts payable to accountants, lawyers and other service providers. Accounts payable are due and in default, and it is possible that persons to whom these obligations are due may seek to collect the amounts due them. The Company's Stock Option Plan is for its employees, directors, officers, and consultants or advisors of the Company. In May, 1995, the Company filed a registration statement on Form S-8 covering 3,000,000 shares of common stock for this Plan. Since May, 1995, holders have exercised options to purchase 597,009 shares of common stock. 48,503 options were exercised during the year ended December 31, 2000, leaving 2,402,991 yet available, with an amended expiration date of March 31, 2002. (See the Company's 14c, filed March 23, 2001). Capital Expenditures and Commitments During the fiscal year ended December 31, 2000, the Company had no capital expenditures. The amount of capital expenditures required is uncertain, and may be beyond that generated from future operations. There can be no assurance that the Company will be able to obtain any such capital or merger acquisition candidate on satisfactory terms. Results of Operations - The fiscal year ended December 31, 2000 compared to the fiscal year ended December 31, 1999. The Company reported no revenues for the current or prior year. During the years ended December 31, 2000 and 1999, operating expenses were $54,802 and $67,627, respectively, primarily consisting of professional and consulting fees. As a result, the Company reported net losses of $54,802 and $67,237, for the years ended December 31, 2000, and 1999, respectively. Factors that may affect future results A number of uncertainties exist that may affect the Company's future operating results, including the possibility of uncertain general economic conditions, market acceptance of the Company's planned future operations, the Company's ability to manage expense growth and the ability to acquire long-term funding (including costs of the Infectech merger). ITEM 7. FINANCIAL STATEMENTS The following financial statements listed in the table below have been prepared in accordance with the requirements of Item 310(a) of Regulation SB (see Item 13). Independent Auditor's Report F-2 Balance Sheet at December 31, 2000 F-3 Statements of Income and Comprehensive Income for the fiscal years ended December 31, 2000, 1999 and 1998 F-4 Statements of Stockholders' Deficit for the fiscal years ended December 31, 2000, 1999 and 1998 F-5 Statements of Cash Flows for the fiscal years ended December 31, 2000, 1999 and 1998 F-6 Notes to the Financial Statements F-8 REGAL ONE CORPORATION AUDITED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2000 AND 1999 Albright, Persing & Associates, Ltd. CERTIFIED PUBLIC ACCOUNTANTS 1025 Ridgeview Dr., Suite 300 Reno, Nevada 89509 Phone (775) 826-5432 FAX (775) 826-5510 REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANT Board of Directors Regal One Corporation We have audited the accompanying balance sheets of Regal One Corporation as of December 31, 2000 and 1999, and the related statements of income and comprehensive income, stockholders' equity (deficit) and cash flows for the years ended December 31, 2000, 1999 and 1998. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statement. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion. In our opinion the financial statements referred to above present fairly, in all material respects, the financial position of Regal One Corporation as of December 31, 2000 and 1999 and the results of its operation and its cash flows for the years ended December 31, 2000, 1999 and 1998 in conformity with generally accepted accounting principles. The accompanying financial statements have been prepared assuming that Regal One Corporation will continue as a going concern. As discussed in Note 1 to the financial statements, the Company's ability to generate sufficient cash flows to meet its obligations, either through future revenues and/or additional debt or equity financing, cannot be determined at this time. In addition, the Company has suffered recurring losses and at December 31, 2000, 1999 and 1998, and has a stockholders' deficit. These uncertainties raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. These financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event the Company cannot continue in existence. /s/ Albright, Persing & Associates, Ltd. Reno, Nevada April 6, 2001 REGAL ONE CORPORATION BALANCE SHEETS December 31, 2000 and 1999 (See Accountants' Audit Report) 2000 1999 ASSETS Current Assets Cash $ 2,336 $ 8 --------- --------- 2,336 8 --------- --------- Other Assets Deferred tax asset, net - - --------- --------- Total Assets $ 2,336 $ 8 ========= ========= LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities Due to stockholders and officers $ 148,003 $ 96,190 Accounts payable and accrued liabilities 124,122 158,296 --------- --------- Total Current Liabilities 272,125 254,486 --------- --------- Stockholders' Equity (Deficit) Series B Preferred stock, no par value. Authorized 50,000,000 shares; issued and outstanding 208,965 shares in 2000 and 1999 500 500 Common stock, no par value. Authorized 50,000,000 shares; issued and outstanding 1,269,716 shares in 2000 and 1,221,217 shares in 1999 6,036,604 5,997,113 Accumulated deficit (6,306,893) (6,252,091) --------- --------- Net Stockholders' Equity (Deficit) (269,789) (254,478) --------- --------- Total Liabilities and Stockholders' Equity (Deficit) $ 2,336 $ 8 ========= ========= The accompanying notes are an integral part of these financial statements.
REGAL ONE CORPORATION STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Years Ended December 31, 2000, 1999 and 1998 (See Accountants' Audit Report) 2000 1999 1998 Expenses: Consulting and outside services $ 21,000 $ 42,000 $ 51,543 Professional services 29,937 21,880 79,711 Other, selling, general and administrative expenses 1,901 3,447 3,143 Interest expense 1,964 - - --------- --------- --------- 54,802 67,327 134,397 --------- --------- --------- Net Income (Loss) (54,802) (67,327) (134,397) Other Comprehensive Income - - - --------- --------- --------- Comprehensive (Loss) $ (54,802) $ (67,327) $ (134,397) ========= ========= ========= Basic and Diluted Loss per Share Before Extraordinary Gain $ (.04) $ (.06) $ (.11) ========= ========= ========= Extraordinary Gain $ - $ - - ========= ========= ========= Basic and Diluted Net Loss per Common Share $ (.04) $ (.06) $ (.11) ========= ========= ========= The accompanying notes are an integral part of these financial statements.
REGAL ONE CORPORATION STATEMENTS OF STOCKHOLDERS' DEFICIT Years Ended December 31, 2000, 1999 and 1998 (See Accountants' Audit Report) Net Stockholders' Preferred Stock Common Stock Accumulated Equity Shares Amount Shares Amount Deficit (Deficit) Balance, December 31, 1997 208,965 $ 500 1,226,342 $5,941,113 $(6,050,367) $ (108,754) Stock issued for cash - - 10,000 56,000 - 56,000 Adjustment to number of shares for share cancellations never issued - - (15,125) - - - Net Loss - - - - (134,397) (134,397) -------- ------- --------- ---------- ----------- ----------- Balance, December 31, 1998 208,965 500 1,221,217 5,997,113 (6,184,764) (187,151) Adjustment to number of shares for share cancellations never issued - - (4) - - - Net (Loss) - - - - (67,327) (67,327) --------- --------- --------- --------- --------- --------- Balance, December 31, 1999 208,965 500 1,221,213 5,997,113 (6,252,091) (254,478) Exercise of stock options - - 48,503 39,491 - 39,491 Net (Loss) - - - - (54,802) (54,802) --------- --------- --------- --------- --------- --------- Balance, December 31, 2000 208,965 500 1,269,716 6,036,604 (6,306,893) (269,789) ========= ========= ========= ========= ========= ========= The accompanying notes are an integral part of these financial statements.
REGAL ONE CORPORATION STATEMENTS OF CASH FLOWS December 31, 2000, 1999 and 1999 (See Accountants' Audit Report) 2000 1999 1998 Cash flows from operating activities: Net income (loss) $ (54,802) $ (67,327) $ (134,397) --------- --------- --------- Adjustments to reconcile net loss to net cash used by operating activities: Noncash consulting fees 21,000 42,000 42,000 Expenses paid by officer 3,384 - 814 Increase (Decrease) in accounts payable and accrued liabilities 17,746 20,517 31,381 --------- --------- --------- Total Adjustments 42,130 62,517 74,195 --------- --------- --------- Net cash used by operating activities (12,672) (4,810) (60,202) --------- --------- --------- Cash flows from financing activities: Proceeds from sale of stock - - 56,000 Proceeds from stockholder loans 15,000 - 8,965 --------- --------- --------- Net cash provided (used) by financing activities 15,000 - 64,965 --------- --------- --------- Net increase (decrease) in cash 2,328 (4,810) 4,763 --------- --------- --------- Cash at beginning of year 8 4,818 55 --------- --------- --------- Cash at end of year $ 2,336 $ 8 $ 4,818 --------- --------- --------- The accompanying notes are an integral part of these financial statements.
REGAL ONE CORPORATION STATEMENTS OF CASH FLOWS December 31, 2000, 1999 and 1998 (See Accountants' Audit Report) SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: 2000 1999 1998 Cash paid during the year for interest $ - $ - $ - ========= ========= ========= Cash paid during the year for income taxes $ - $ - $ - ========= ========= ========= SUPPLEMENTAL DISCLOSURE OF NON-CASH OPERATING AND FINANCING TRANSACTIONS: During the year ended December 31, 2000, a stockholder exercised stock options into 48,503 shares of common stock for payments of $26,531 to accounts payable vendors and $12,960 due to officers. During the year ended December 31, 2000, an accounts payable liability of $25,389 was reclassified to due to stockholders/officers. The accompanying notes are an integral part of these financial statements.
REGAL ONE CORPORATION NOTES TO FINANCIAL STATEMENTS December 31, 2000, 1999 and 1998 NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES Regal One Corporation (the "Company") located in Las Vegas, Nevada, is a Florida Corporation originally incorporated as Electro-Mechanical Services, Inc., in 1959 in Florida. The Company has been involved in a variety of industries including automobile mufflers, real estate, and the pharmaceutical and health fields. The Company is currently not in formal business operations, but is actively seeking a merger candidate. The Company has not generated significant revenue during the years ended December 31, 2000, 1999 and 1998, and has funded its operation primarily through the issuance of equity. Accordingly, the Company's ability to accomplish its business strategy and to ultimately achieve profitable operations is dependent upon its ability to obtain additional debt or equity financing, or to merge with a going concern Company. There can be no assurance that the Company will be able to obtain additional funding, and, if available, will be obtained on terms favorable to or affordable by the Company. The Company's management is currently exploring a merger option. Ultimately, however, the Company will need to achieve profitable operations and/or merge with a going concern Company in order to continue as a going concern. In addition, the Company has suffered recurring losses and at December 31, 2000 has a shareholders' deficit. These factors indicate that the Company's ability to continue as a going concern is dependent upon the Company obtaining additional financing to satisfy the operating needs of the Company. The Company is seeking a merger candidate and believes that a successful merger will occur in the near future. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. Cash and Cash Equivalents Cash and cash equivalents consist of cash balances and instruments with maturities of three months or less at the time of purchase. Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Fair Value of Financial Instruments Effective July 1, 1994, the Company adopted Statement of Financial Accounting Standards No. 107, "Disclosures about Fair Value of Financial Instruments" ("SFAS No. 107"). The carrying amounts reported in the balance sheet for cash and cash equivalents approximate those assets' fair values. Active markets for the Company's other financial instruments that are subject to the fair value disclosure requirements of SFAS No. 107 do not exist and there are no quoted market prices for these instruments. Accordingly, it is not practicable to estimate the fair values of such financial instruments because of (1) the limited information available to the Company, (2) the significance of the cost to obtain independent appraisals for this purpose, and (3) due to the immateriality of such amounts. Income Taxes In February, 1992, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes" ("SFAS No. 109"). SFAS No. 109 required a change from the deferred method of accounting for income taxes of APB Opinion 11 to the asset and liability method of accounting for income taxes. Under the asset and liability method of SFAS No. 109, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under SFAS No. 109, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Effective January 1, 1993, the Company adopted SFAS No. 109. The application of SFAS No. 109 had an immaterial effect on the Company's financial statements for the periods prior to January 1, 1993 due to operating losses incurred by the Company in 1993 and prior years. Concentrations of Credit Risk Financial instruments which potentially subject the Company to credit risk consist primarily of cash in bank. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Earnings per share In February, 1997, the Financial Accounting Standards Board issued SFAS No. 128, Earnings per Share. SFAS No. 128 simplifies the standards for computing earnings per share ("EPS") and was effective for financial statements issued for periods ending after December 15, 1997, with earlier application not permitted. Upon adoption, all prior EPS data was restated. Basic EPS is determined using net income divided by the weighted average shares outstanding during the period. Diluted EPS is computed by dividing net income by the weighted average shares outstanding, assuming all dilutive potential common shares were issued. Since the fully diluted loss per share for 2000, 1999 and 1998 was antidilutive, basic and diluted earnings per share are the same. Accordingly, options to purchase common stock in 2000, 1999 and 1998 of 2,451,494 shares, and 20,896,500 common shares potentially issuable upon conversion of preferred stock existing at the end of 2000, 1999 and 1998 were not included in the calculation of diluted earnings per common share. New Accounting Standards In June, 1997, the Financial Accounting Standards Board issued SFAS No. 130, Reporting Comprehensive Income. SFAS No. 130 establishes standards for reporting and presentation of comprehensive income and its components in a full set of general- purpose financial statements. This statement does not, however, require a specific format for the disclosure, but requires the Company to display an amount representing total comprehensive income for the period in its financial statements. Comprehensive income is determined by adjusting net income by other items not included as a component of net income, such as the unrealized gain (loss) on certain marketable securities. During the periods presented, the Company had no additional components that were not a part of net income (loss), therefore, comprehensive income and net income are the same amount. In June, 1997, the Financial Accounting Standards Board issued SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information. SFAS No. 131 establishes standards for the manner in which public business enterprises report information about operating segments in annual financial statements and requires that those enterprises report selected information about operating segments in interim financial reports issued to shareholders. This statement also requires that a public business enterprise report financial and descriptive information about its reportable operating segments. The Company is currently not in formal business operations and does not have any reportable operating segments. In June, 1998, the Financial Accounting Standards Board issued SFAS 133, Accounting for Derivative Instruments and Hedging Activities, however, the effective date for this pronouncement was delayed for one year from the original effective date of fiscal years beginning after June 15, 1999. Since the Company does not deal in derivative instruments or hedging activities, it is anticipated that this pronouncement will have no impact on the Company's financial statements. NOTE 2 - PRIOR PERIOD ADJUSTMENT The accompanying financial statements for 1998 have been restated to correct an error made in 1994 when 30,000 shares of common stock that had been issued in 1993 were incorrectly canceled. The effect of the restatement had no impact on net income for 1998. However, the number of shares of common stock outstanding for 1998 have been adjusted to reflect the additional 30,000 shares. NOTE 3 - STOCKHOLDERS' DEFICIT The authorized number of shares of preferred stock is 50,000,000. The Company's bylaws allow for segregating this preferred stock into separate series. As of December 31, 2000, the Company has authorized 50,000 shares of series A preferred stock and 50,000,000 shares of series B convertible preferred stock. At December 31, 2000, 1999 and 1998, there were no outstanding shares of series A preferred stock. At December 31, 2000, 1999 and 1998, 208,965 shares of series B preferred stock were outstanding. Holders of series A preferred stock shall be entitled to voting rights equivalent to 1,000 shares of common stock. The series A preferred stock has certain dividend and liquidation preferences over common stockholders. Holders of series B preferred stock shall be entitled to voting rights equivalent to 100 shares of common stock. The series B preferred stock is entitled to a noncumulative dividend of 8.75% of revenues which exceed $5,000,000. At the option of the holder of series B preferred stock, each share can be converted to common stock at a rate of 100 shares of common for each share of preferred. As of December 31, 2000, 1999 and 1998, no dividends have been declared on the series A or series B convertible preferred stock. NOTE 4 - STOCK OPTIONS On May 3, 1995, the Company adopted a stock option plan to provide incentives to those individuals who serve or have served the Company as employees, officers, directors or consultants. Under the plan, the Board of Directors is authorized to grant option to individuals who have contributed, or will contribute to the well being of the Company. The Company applies APB Opinion 25 in accounting for its fixed stock option plan. Accordingly, since the market value and the option price of the Company's stock were equal on the measurement date, no compensation cost has been recognized for the plan in 2000, 1999 or 1998. Had compensation cost been determined on the basis of fair value pursuant to FASB Statement No. 123, net income (loss) and earnings per share would have been impacted as follows: 2000 1999 1998 Net Income (Loss) As reported $ 54,802 $ (67,327) $ 134,397 ========== =========== ========== Pro forma $ 54,802 $ (67,327) $ (338,246) ========== =========== ========== Basic Earnings Per Share As reported $ .04 $ (.06) $ (.11) ========== =========== ========== Pro forma $ .04 $ (.06) $ (.29) ========== =========== ========== Diluted Earnings Per Share As reported $ .04 $ (.06) $ (.11) ========== =========== ========== Pro forma $ .04 $ (.06) $ (.29) ========== =========== ========== For purposes of estimating the fair value of each option granted in accordance with FASB 123, the Black-Scholes Model was used for 1998 and 1997. The following assumptions were made in estimating fair value: Dividend yield 0% Risk-free interest rate 5.50% to 8.50% Expected life 3 years Expected volatility 124.42% Compensation expense that would have been charged to operations had the provisions of FASB 123 been applied were $203,849 for the year ended December 31, 1998. For the years ended December 31, 2000 and 1999, no options were issued or vested, and therefore, there would be no compensation expense. Following is a summary of the Company's stock option activity and status of options outstanding during the years ended December 31: Year Ended 12/31/00 Weighted Number Average of Exercise Shares Price Outstanding at January 1 2,451,494 $ .8125 Granted - - Exercised - - Forfeited (48,503) .8125 --------- -------- Outstanding at December 31 2,402,991 $ .8125 ========= ======== Year Ended 12/31/99 Year Ended 12/31/98 Weighted Weighted Number Average Number Average of Exercise of Exercise Shares Price Shares Price Outstanding at January 1 2,451,494 $ .8125 2,451,494 $ .8125 Granted - - - - Exercised - - - - Forfeited - - - - --------- -------- --------- -------- Outstanding at December 31 2,451,494 $ .8125 2,451,494 $ .8125 ========= ======== ========= ======== There were no options granted during 2000, 1999 and 1998. The following table summarizes information regarding stock options outstanding at December 31, 2000: Outstanding Options Exercisable Options - ----------------------------------------- --------------------------------- Weighted Average Weighted Weighted Remaining Average Average Exercise Contractual Exercise Exercise Price Range Number Life Price Number Price - ----------- ----------- ------------ -------- ----------- -------- $ .8125 2,402,991 1.25 Years $ .8125 2,402,991 $ .8125
NOTE 5 - EARNINGS PER SHARE The following data show the amounts used in computing earnings per share and the effect on income and the weighted average number of shares of dilutive potential common stock. 2000 1999 1998 ---------- ---------- ---------- Income from continuing operations before extraordinary items $ (54,802) $ (67,327) $ (134,397) Less: preferred dividends - - - ---------- ---------- ---------- Income available to common stockholders used in basic EPS $ (54,802) $ (67,327) $ (134,397) ========== ========== ========== Income available to common stockholders used in basic EPS $ (54,802) $ (67,327) $ (134,397) Convertible preferred stock - - - ---------- ---------- ---------- Income available to common stockholders after assumed conversions of dilutive securities $ (54,802) $ (67,327) $ (134,397) ========== ========== ========== Weighted average number of common shares used in basic EPS 1,250,799 1,212,610 1,212,614 Effect of dilutive securities: Stock options - - - Convertible preferred stock - - - ---------- ---------- ---------- Weighted number of common shares and dilutive potential common stock used in diluted EPS 1,250,799 1,212,610 1,212,614 ========== ========== ==========
NOTE 6 - INCOME TAXES As discussed in Note 1, the Company adopted Statement of Financial Accounting Standards No. 109 effective January 1, 1993. One of the provisions of Statement 109 enables companies to record deferred tax assets for the benefit to be derived from the utilization of net operating loss carryforwards and certain deductible temporary differences. At December 31, 2000, 1999 and 1998, the tax effects of temporary differences that give rise to significant portions of deferred tax assets are presented below: 2000 1999 1998 --------- --------- --------- Net operating loss carryforwards $ 663,350 $ 631,972 $ 627,617 Less: valuation allowance (663,350) (631,972) (627,617) --------- --------- --------- $ - $ - $ - ========= ========= ========= Due to operating losses incurred by the Company, the Company established a related valuation allowance of $663,350 at December 31, 2000. As of December 31, 2000, the Company has net operating loss carryforwards of approximately $1,951,030 for Federal income tax return purposes, which expire through 2015. Additionally, the Company has $92,040 in unpaid consulting expenses due to a related party. The future tax benefits are dependent upon the Company's ability to generate future earnings. NOTE 7 - SUBSEQUENT EVENT On March 23, 2001, the Company amended their Stock Option Plan to extend the expiration date of granted options from March 31, 2001 to March 31, 2002. At December 31, 2000, the Company had 2,402,991 options granted related to the Plan, with an exercise price of $.8125 per option. ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE There have been no disagreements with accountants with respect to accounting and/or financial disclosure for any periods reported on in this Form 10-KSB. PART III ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS: COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT The following table sets forth certain information concerning the current directors and executive officers of the Company: Name Age Position Dr. Malcolm R. Currie 73 Chairman of the Board Richard Babbit 74 Secretary, Treasurer and Director, and President Michael Platt 58 Director Each director holds office for a one-year term until his successor has been elected and qualified at the annual meeting of the Company's shareholders. The members of the Board of Directors serve without remuneration. Corporate Officers are elected by the Board of Directors and serve at the discretion of the Board. Israel Rubinstein died during the reporting period and was replaced in his various capacities by Dr. Malcolm Currie. Dr. Malcolm Currie was appointed as Chairman of the Board of Directors of the Company in August, 1995. From 1969 to 1973, Dr. Currie was the Undersecretary of Research and Engineering for the Office of Defense. From 1973 to 1977, Dr. Currie was President of the Missile Systems Group for Hughes Aircraft Corporation. From 1977 to 1988, Dr. Currie started as Executive Vice President and eventually became Chief Executive Officer and Chairman of the Board of Delco Electronics Corporation. From 1992 to present, Dr. Currie has been Chairman Emeritus of Hughes Aircraft Corporation. Dr. Currie is also on the Board of Directors of Unocal Oil. Dr. Currie obtained a graduate MBA from the University of California, Berkeley, and a PhD in Research Engineering at the University of California, Berkeley. Richard Babbitt was appointed as the Secretary and Treasurer and a member of the Board of Directors of the Company in August, 1995. Mr. Babbitt has been the President of the Medical Supply Company, Bl Industries, American Safety Equipment Corporation, and Bl Advisors. Mr. Babbitt is an international marketing consultant to Teikuro Corporation and Cosmo Corporation in Japan. Mr. Babbitt is also a member of the Board of Directors of Unisyn Biowaste Technology and Interstate Safety Corporation. Mr. Babbitt obtained an undergraduate degree from Purdue University. Mr. Michael E. Platt was appointed as a member of the Board of the Directors of the Company in August, 1995. Michael E. Platt is President of Fresh Food Ventures, Inc. Mr. Platt co-founded Peerless Industrial Group, Inc. ("Peerless") in 1983, and was responsible for building it to an organization of more than 500 people, raising capital, taking the company public in 1985 and developing 12 Fuddruckers Restaurants in four Midwestern states. In 1994, Peerless sold its Fuddruckers Restaurants and in 1995 completed the acquisition of the Peerless Chain Company, a major domestic marketer of various chain products. Mr. Platt served as a Director of New Products for Kentucky Fried Chicken Corporation, and in various marketing positions at General Foods Corporation. Compliance with Section 16 of The Securities Exchange Act of 1934 To the Company's knowledge, based on a review of such materials as are required by the SEC, no officer, director, or beneficial holder of more than five percent of the Company's issued and outstanding shares of common stock has filed with the SEC any form or report required to be so filed pursuant to section 16(a) of the Securities Exchange Act of 1934 during the fiscal year ended December 31, 1999 or prior thereto (see Item 11 for a list of the Company's officers, directors and beneficial holders of more than five percent of the Company's issued and outstanding shares of common stock). Based solely on a review of such materials as is required by the SEC, the Company is not aware of any transactions that were not reported. ITEM 10. EXECUTIVE COMPENSATION There was no cash compensation paid by the Company to the executive officers of the Company for the fiscal years ended December 31, 2000 and 1999. ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The persons set forth on the chart below are known to the Company to be the beneficial owners of more than five percent of the Company's outstanding voting common stock as of March 31, 2001. Information concerning the number and percentage of shares of voting common stock of the Company owned on record and beneficially by management is set forth on the chart below: Shares of common Percent of Name and Address of stock beneficially common stock beneficial owner owned owned Ahuva Rubinstein 131,840 10.9% 551 Drift Stone Avenue Las Vegas, Nevada 89123 Yifal Shaham 60,625 5.0% 9720 Holcolm Street Los Angeles, CA 90035 All Directors and Officers 131,840 10.9% as a group (4 persons) (1) Based upon 1,196,342 shares of common stock issued and outstanding as of March 31, 2001. This does not take into account 208,965 shares of Preferred stock representing in the aggregate 24,296,500 common shares votes. Each share of Preferred Stock is convertible into 100 shares of voting common stock. Of the Preferred Stock outstanding, 96,750 shares (46.3%) are held by the Directors of the Company (Dr. Malcolm Currie, 30,000 shares; Richard Babbit, 30,000 shares; Michael Platt, 36,750 shares). ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS None. ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K Exhibits None. A copy of any of the exhibits listed or referred to above will be furnished at a reasonable cost to any person who was a shareholder of the Company on March 31, 2001 upon receipt from any such person of written request for any such exhibit. Such request should be sent to the Company with the attention directed to the Corporate Secretary. Reports on Form 8-K In April, 1998, the Company entered into a Plan and Agreement of Merger with Infectech, a Delaware Corporation ("Infectech"). The Company would have issued approximately 26,320,520 Shares of common stock to Infectech's stockholders so that on the effective date of the merger, the shareholders of Infectech would own, in the aggregate, 85% of the common stock of the Company. Upon closing, the Company would have changed its name to Infectech, Inc., and the shareholders of Regal One as a group would own 15%. The Board of Directors of Infectech would have become the Board of Directors of the Company. For each share of Infectech's issued and outstanding common stock, its stockholders would have received approximately 3.01 shares of Regal One common stock, subject to further adjustment downward for issuances of securities by Infectech pursuant to stock options, consulting agreements or other private offerings. The Company was to cause holders of its Preferred Stock to convert their shares into an aggregate of not more than 3,447,923 shares of common stock, which together with a current 1,196,342 Shares of common stock outstanding, would have resulted in a total of 30,964,785 shares to be outstanding upon closing of the merger. The transaction was contingent upon the approval of the shareholders of both companies, upon certain regulatory approvals and other conditions. One condition of the merger was that the Securities and Exchange Commission must declare effective the Company's registration of the Shares of common stock to be issued to Infectech. Another condition of the merger was that Infectech raise a minimum of $300,000 through an offering or other funding source prior to June 30, 1998. On August 5, 1998, the Company announced that Infectech unilaterally acted to terminate the merger agreement between the two parties. Infectech stated as its reason that it had not been successful in raising the requisite $300,000 prior to June 30, 1998. Infectech further notified the Company that it proposed to arbitrate the return of $56,000 paid by Infectech for legal fees and certain other merger-related expenses of the Company, as per the merger agreement. On November 18, 1998, the Company and Infectech resolved the matter subject to arbitration, with the Company issuing 10,000 shares of restricted common stock to Infectech on November 24, 1998. SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act, the Company has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REGAL ONE CORPORATION Date: April 10, 2001 /s/ Richard Babbitt Richard Babbitt, President In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the Company and in the capacities end on the dates indicated. /s/ Richard Babbitt April 10, 2001 Richard Babbitt President, Secretary, Treasurer & Director /s/ Malcolm R. Currie April 10, 2001 Dr. Malcolm R. Currie Chairman & Director /s/ Michael E. Platt April 10, 2001 Michael E. Platt Director